Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 24812389)


AIDS/HIV. Host controls of HIV neutralizing antibodies.

Haynes BF, Verkoczy L.

Science. 2014 May 9;344(6184):588-9. doi: 10.1126/science.1254990. No abstract available.


HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.

Moody MA, Yates NL, Amos JD, Drinker MS, Eudailey JA, Gurley TC, Marshall DJ, Whitesides JF, Chen X, Foulger A, Yu JS, Zhang R, Meyerhoff RR, Parks R, Scull JC, Wang L, Vandergrift NA, Pickeral J, Pollara J, Kelsoe G, Alam SM, Ferrari G, Montefiori DC, Voss G, Liao HX, Tomaras GD, Haynes BF.

J Virol. 2012 Jul;86(14):7496-507. doi: 10.1128/JVI.00426-12. Epub 2012 May 2.


AIDS/HIV. A boost for HIV vaccine design.

Burton DR, Weiss RA.

Science. 2010 Aug 13;329(5993):770-3. doi: 10.1126/science.1194693. No abstract available.


Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

Bonsignori M, Montefiori DC, Wu X, Chen X, Hwang KK, Tsao CY, Kozink DM, Parks RJ, Tomaras GD, Crump JA, Kapiga SH, Sam NE, Kwong PD, Kepler TB, Liao HX, Mascola JR, Haynes BF.

J Virol. 2012 Apr;86(8):4688-92. doi: 10.1128/JVI.07163-11. Epub 2012 Feb 1.


Antibodies in HIV-1 vaccine development and therapy.

Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC.

Science. 2013 Sep 13;341(6151):1199-204. doi: 10.1126/science.1241144. Review.


Dancing with an escape artist.

Deweerdt S.

Nature. 2010 Jul 15;466(7304):S6-7. doi: 10.1038/nature09237. No abstract available.


Tiny steps towards an HIV vaccine.

Willyard C.

Nature. 2010 Jul 15;466(7304):S8. doi: 10.1038/nature09238. No abstract available.


Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies.

Pujanauski LM, Janoff EN, McCarter MD, Pelanda R, Torres RM.

Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1422-7. doi: 10.1073/pnas.1213713110. Epub 2013 Jan 3.


Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.

Kumar R, Tuen M, Liu J, Nàdas A, Pan R, Kong X, Hioe CE.

Vaccine. 2013 Nov 4;31(46):5413-21. doi: 10.1016/j.vaccine.2013.09.010. Epub 2013 Sep 16.


Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.

Douagi I, Forsell MN, Sundling C, O'Dell S, Feng Y, Dosenovic P, Li Y, Seder R, Loré K, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

J Virol. 2010 Feb;84(4):1683-95. doi: 10.1128/JVI.01896-09. Epub 2009 Dec 2.


B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.

Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD.

Trends Mol Med. 2011 Feb;17(2):108-16. doi: 10.1016/j.molmed.2010.10.008. Epub 2010 Nov 26.


Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.

Chen Y, Zhang J, Hwang KK, Bouton-Verville H, Xia SM, Newman A, Ouyang YB, Haynes BF, Verkoczy L.

J Immunol. 2013 Aug 1;191(3):1260-75. doi: 10.4049/jimmunol.1300770. Epub 2013 Jul 3.


AIDS research. Novel antibody response may explain HIV vaccine success.

Cohen J.

Science. 2011 Sep 16;333(6049):1560. doi: 10.1126/science.333.6049.1560. No abstract available.


Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.

Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC.

PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013.


Neutralizing antibodies to HIV-1 induced by immunization.

McCoy LE, Weiss RA.

J Exp Med. 2013 Feb 11;210(2):209-23. doi: 10.1084/jem.20121827. Review.


Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies.

Montefiori DC, Evans TG.

AIDS Res Hum Retroviruses. 1999 May 20;15(8):689-98. No abstract available.


A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR.

PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.


Recent strategies targeting HIV glycans in vaccine design.

Horiya S, MacPherson IS, Krauss IJ.

Nat Chem Biol. 2014 Dec;10(12):990-9. doi: 10.1038/nchembio.1685. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk